Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRY805 in advanced solid tumors
NCT06289894Phase 1Terminated
- Sponsor
- BioRay Pharmaceutical
- Start
- Mar 2024
- Primary completion
- May 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BRY805 in solid tumor (advanced stage), sponsored by BioRay Pharmaceutical. Primary endpoints: Dose-Limiting Toxicity at 21 days and Treatment-Emergent Adverse Event at 91 days. Started Mar 2024; status: terminated.
02
Drugs
BRY805
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06289894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06289894.